SCHEMBL1744612

SCHEMBL1744612

COC(=O)CCc1ccc(OC2CCc3cc(OCc4ccccc4)ccc32)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 5/20 0.48
GHSR Q92847 2/20 0.47
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
RXRG P48443 1/20 0.47
FFAR4 Q5NUL3 1/20 0.46
MMP1 P03956 2/20 0.45
MMP2 P08253 2/20 0.45
MMP7 P09237 2/20 0.45
MMP9 P14780 2/20 0.45
MMP12 P39900 2/20 0.45
MMP14 P50281 2/20 0.45
MMP15 P51511 2/20 0.45
MMP16 P51512 2/20 0.45
MMP26 Q9NRE1 2/20 0.45
LIPG Q9Y5X9 1/20 0.45
GAA P10253 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2B Q13224 1/20 0.43
FAAH O00519 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1746434 0.93 RXRA (0.47) FFAR1GHSRRXRARXRBRXRG
SCHEMBL1744689 0.92 FFAR1 (0.46) FFAR1
SCHEMBL1745404 0.90 FFAR1 (0.47) FFAR1GRIN1GRIN2B
SCHEMBL1746547 0.90 FFAR1 (0.61) FFAR1RXRARXRBRXRGFFAR4
SCHEMBL1744736 0.88 FFAR1 (0.44) FFAR1FFAR4GRIN1GRIN2B
SCHEMBL1744583 0.87 GFRA3 (0.49) FFAR1FFAR4
SCHEMBL1747248 0.87 GRIN2B (0.44) FFAR1GRIN1GRIN2BMAPT
SCHEMBL1745440 0.86 GFRA3 (0.48) FFAR1FFAR4
SCHEMBL1744692 0.84 FFAR1 (0.52) FFAR1MAPTMAPK1
SCHEMBL1745225 0.84 FFAR1 (0.52) FFAR1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885GHSR 6/4885RXRA 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.